← Back to Search

Monoclonal Antibodies

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

Phase < 1
Waitlist Available
Led By Yael Renert-Yuval, MD
Research Sponsored by Rockefeller University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing Brodalumab, a medication for treating hidradenitis suppurativa. It aims to help patients with this painful skin condition by reducing swelling and pain through blocking inflammation signals.

Eligible Conditions
  • Hidradenitis suppurativa
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Interleukin-17 receptor A (IL-17RA) saturation during brodalumab administration at week 12 vs baseline
Secondary study objectives
Change in levels of IL-17A, IL-17C, IL-17, CXCL1, and CXCL8
Correlate IL-17R saturation (measured by the frequencies of immune cells positive to IL-17RA by flow cytometry) with clinical measures, such as pain or the Hidradenitis Suppurativa Severity Score System (IHS4)

Side effects data

From 2019 Phase 4 trial • 210 Patients • NCT03331835
34%
Viral upper respiratory tract infection
13%
Headache
9%
Arthralgia
8%
Overdose
6%
Back pain
6%
Nausea
6%
Oropharyngeal pain
6%
Pruritus
5%
Fatigue
5%
Depressive symptom
4%
Diarrhoea
2%
Abdominal pain
2%
Abdominal pain upper
2%
Lymphopenia
1%
Reactive gastropathy
1%
Pancreatic carcinoma metastatic
1%
Stasis dermatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Brodalumab 210 mg
Fumaric Acid Ester

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Brodalumab treated moderate-to-severe HS patientsExperimental Treatment1 Intervention
Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brodalumab
FDA approved

Find a Location

Who is running the clinical trial?

Rockefeller UniversityLead Sponsor
160 Previous Clinical Trials
16,522 Total Patients Enrolled
3 Trials studying Hidradenitis Suppurativa
10 Patients Enrolled for Hidradenitis Suppurativa
Yael Renert-Yuval, MDPrincipal Investigator - The Rockefeller University
Rockefeller University
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top